Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Reduction of Natural Killer Cell (CD16/56) and T-lymphocyte (CD3) Subset Counts After a Weight Loss Program Using Anti-obesity Drugs in Obese Women: a Non-randomized Controlled Trial

NCT03336086 is registered in ClinicalTrials.gov with Shiraz University of Medical Sciences as lead sponsor.

NCT NCT03336086
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03336086 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Reduction of Natural Killer Cell (CD16/56) and T-lymphocyte (CD3) Subset Counts After a Weight Loss Program Using Anti-obesity Drugs in Obese Women: a Non-randomized Controlled Trial
Lead sponsor
Shiraz University of Medical Sciences
Phase
Phase 3
Overall status
Completed
Start date
March 20, 2012
Completion date
December 25, 2012
Enrollment
29 (actual)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

anti-obesity agents, immunity, lymphocytes, viral diseases, weight loss